Week In Review: Otsuka Pays $78 Million For Asian Rights To Ariad's Leukemia Drug

Otsuka will pay $77.5 million upfront plus additional regulatory milestones. Ariad will receive a "substantial" share of net product revenues.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.